-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-10-16
Values as of: 2019-10-16
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Russell Top 200 Equal Weight Index (the "underlying index"). The fund generally will invest at least 90% of its total assets in the component securities that comprise the underlying index. The underlying index is designed to provide equal-weighted exposure to the securities of the largest 200 companies in the U.S. equity market.
Company Website : www.invescopowershares.com
Currency: USD
Country : USA
Inception Date: 01/12/2006
Primary Benchmark: S&P 100 Equal Weighted TR USD
Primary Index: S&P 500 TR USD
Gross Expense Ratio: 0.54%
Management Expense Ratio: 0.25 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| SCPS | Scopus Biopharma Inc | 1.17 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| SOJE | SOJE | 0.00 % |
+0.04 (+0.21%) |
USD 65.72B |
| JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.11 (-0.20%) |
USD 32.78B |
| LCR | Leuthold Core ETF | 0.00 % |
-0.09 (-0.27%) |
USD 32.52B |
| DTB | DTB | 0.00 % |
-0.12 (-0.63%) |
USD 26.58B |
| DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.03 (-0.10%) |
USD 26.11B |
| JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
N/A |
USD 22.47B |
| SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
| TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.07 (-0.22%) |
USD 16.23B |
| DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.04 (+0.10%) |
USD 10.15B |
| AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+0.02 (+0.02%) |
USD 10.05B |
N/A
| Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 17.58% | 75% | C | 67% | D+ | ||
| Dividend Return | 1.32% | 46% | F | 30% | F | ||
| Total Return | 18.90% | 75% | C | 64% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | 5.26% | 65% | D | 61% | D- | ||
| Dividend Return | 1.19% | 29% | F | 21% | F | ||
| Total Return | 6.45% | 61% | D- | 56% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 56.43% | 86% | B+ | 79% | B- | ||
| Dividend Return | 10.86% | 52% | F | 37% | F | ||
| Total Return | 67.29% | 86% | B+ | 78% | C+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 8.56% | 87% | B+ | 77% | C+ | ||
| Dividend Return | 10.32% | 87% | B+ | 75% | C | ||
| Total Return | 1.76% | 55% | F | 39% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 9.90% | 53% | F | 71% | C- | ||
| Risk Adjusted Return | 104.30% | 90% | A- | 90% | A- | ||
| Market Capitalization | 0.03B | 42% | F | 18% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
